The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
News the HIV world has been waiting for – long-acting injectable cabotegravir (CAB-LA) is a potentially game-changing tool to prevent HIV in women.
Test and treat analysis from Eastern Uganda finds 90% of people diagnosed start treatment – but one in five has left care after 12 months
Government initiative increases retention in care by a third but struggles to expand treatment access or reduce deaths among people with HIV.
User fees lead to a ‘drastic’ fall in the number of people starting HIV care at a PEPFAR-funded clinic in Lagos.
The first evidence review to focus on men who buy sex – rather than women who sell it – finds a strong association between purchasing sex and HIV.
Study among fisherfolk, sex workers, truck drivers and others at higher risk of HIV finds many are willing to try PrEP – but only for around six weeks.
We talk to Giffin Daughtridge, CEO of medical diagnostics company, UrSure, about treatment adherence and the impact of long-acting cabotegravir as injectable PrEP.
The 23rd International AIDS Conference (AIDS 2020 Virtual) kicked-off with a clear message from UNAIDS to accelerate efforts to end AIDS and not be derailed by COVID-19.
The proportion of South Africans ever testing for HIV increased from 30% to 75% between 2005 and 2017 – but differences remain in who is getting tested
HIV drug resistance among treatment-naïve people in China rising rapidly from 2012 and tops 10% in Central China.
We have launched a new mobile app made in collaboration with community health workers in Southern Africa. Find out all you need to know about Boost!